Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
This study aims to compare gadoteridol with ferumoxytol for contrast-enhanced and perfusion-weighted (PW) MRI of intracranial tumors. The final analysis included 26 patients, who underwent 3 consecutive days of 3T MRI. Day 1 consisted of anatomical pre- and postcontrast images, and PW MRI was acquired using gadoteridol (0.1 mmol/kg). On Day 2, the same MRI sequences were obtained with ferumoxytol (510 mg) and on Day 3, the anatomical images were repeated to detect delayed ferumoxytol-induced signal changes. The T₁-weighted images were evaluated qualitatively and quantitatively for enhancement volume and signal intensity (SI) changes; PW data were used to estimate the relative cerebral blood volume (rCBV). All 26 lesions showed 24-hour T₁-weighted ferumoxytol enhancement; 16 also had T₂-weighted hypointensities. In 6 patients, ferumoxytol-induced signal changes were noted in areas with no gadoteridol enhancement. Significantly greater (P< .0001) SI changes were seen with gadoteridol, and qualitative analyses (lesion border delineation, internal morphology, contrast enhancement) also showed significant preferences (P= .0121; P = .0015; P < .0001, respectively) for this agent. There was no significant difference in lesion enhancement volumes between contrast materials. The ferumoxytol-rCBV values were significantly higher (P = .0016) compared with the gadoteridol-rCBV values. In conclusion, ferumoxytol provides important information about tumor biology that complements gadoteridol imaging. The rCBV measurements indicate areas of tumor undergoing rapid growth, whereas the 24-hour scans mark the presence of inflammatory cells. Both of these functions provide useful information about tumor response to treatment. We suggest that dynamic and anatomical imaging with ferumoxytol warrant further assessment in brain tumor therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Weinstein, J. S., Varallyay, C. G., Dosa, E., Gahramanov, S., Hamilton, B., Rooney, W. D., Muldoon, L. L., & Neuwelt, E. A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.192 · Cited by 500
Self-citationNeuwelt, E. A., Hamilton, B. E., Varallyay, C. G., Rooney, W. R., Edelman, R. D., Jacobs, P. M., & Watnick, S. G. (2009) · Kidney International · doi:10.1038/ki.2008.496 · Cited by 267
Neuwelt, E. A., Várallyay, C. G., Manninger, S., Solymosi, D., Haluska, M., Hunt, M. A., Nesbit, G., Stevens, A., Jerosch-Herold, M., Jacobs, P. M., et al. (2007) · Neurosurgery · doi:10.1227/01.neu.0000255350.71700.37 · Cited by 184
Self-citation
Cited by
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
A Review of Clinical Translation of Inorganic Nanoparticles
Anselmo, A. C., & Mitragotri, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9780-2 · Cited by 509
Emerging applications for ferumoxytol as a contrast agent in MRI
Bashir, M. R., Bhatti, L., Marin, D., & Nelson, R. C. (2015) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24691 · Cited by 371
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
Muldoon, L. L., Alvarez, J. I., Begley, D. J., Boado, R. J., del Zoppo, G. J., Doolittle, N. D., Engelhardt, B., Hallenbeck, J. M., Lonser, R. R., Ohlfest, J. R., et al. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.153 · Cited by 321
Self-citationCurrent and potential imaging applications of ferumoxytol for magnetic resonance imaging
Toth, G. B., Varallyay, C. G., Horvath, A., Bashir, M. R., Choyke, P. L., Daldrup-Link, H. E., Dosa, E., Finn, J. P., Gahramanov, S., Harisinghani, M., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.12.037 · Cited by 317
“Contrast enhancement found on various clinically used T1-weighted MRI sequences improves border delineation and enables assessment of lesion internal morphology (Figure 4).(36,37) In primary malignant brain tumors, contrast enhancement with ferumoxytol is comparable with GBCA enhancement.”
Self-citation
Metadata
- Authors
- Dosa, E., Guillaume, D. J., Haluska, M., Lacy, C. A., Hamilton, B. E., Njus, J. M., Rooney, W. D., Kraemer, D. F., Muldoon, L. L., & Neuwelt, E. A.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-12-16
- Volume
- 13
- Issue
- 2
- Pages
- 251-260
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2154155058
- Cited by
- 55
- References
- 4
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. https://app.cochat.ai/papers/10.1093/neuonc/noq172
- The paper
- Dosa, E., Guillaume, D. J., Haluska, M., Lacy, C. A., Hamilton, B. E., Njus, J. M., Rooney, W. D., Kraemer, D. F., Muldoon, L. L., & Neuwelt, E. A. (2011). Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. Neuro-Oncology. https://doi.org/10.1093/neuonc/noq172
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.